Body Mass Index at Pediatric Leukemia Diagnosis and the Risks of Relapse and Mortality: Findings from a Single Institution and Meta-analysis by Saenz, Ashleigh M. et al.
University of South Florida 
Scholar Commons 
Epidemiology and Biostatistics Faculty 
Publications Epidemiology and Biostatistics 
2018 
Body Mass Index at Pediatric Leukemia Diagnosis and the Risks 
of Relapse and Mortality: Findings from a Single Institution and 
Meta-analysis 
Ashleigh M. Saenz 
University of South Florida 
Stacie Stapleton 
John Hopkins University School of Medicine 
Raquel G. Hernandez 
John Hopkins University School of Medicine 
Greg A. Hale 
John Hopkins University School of Medicine 
Neil A. Goldenberg 
John Hopkins University School of Medicine 
See next page for additional authors 
Follow this and additional works at: https://scholarcommons.usf.edu/epb_facpub 
Scholar Commons Citation 
Saenz, Ashleigh M.; Stapleton, Stacie; Hernandez, Raquel G.; Hale, Greg A.; Goldenberg, Neil A.; Schwartz, 
Skai W.; and Amankwah, Ernest K., "Body Mass Index at Pediatric Leukemia Diagnosis and the Risks of 
Relapse and Mortality: Findings from a Single Institution and Meta-analysis" (2018). Epidemiology and 
Biostatistics Faculty Publications. 5. 
https://scholarcommons.usf.edu/epb_facpub/5 
This Article is brought to you for free and open access by the Epidemiology and Biostatistics at Scholar Commons. 
It has been accepted for inclusion in Epidemiology and Biostatistics Faculty Publications by an authorized 
administrator of Scholar Commons. For more information, please contact scholarcommons@usf.edu. 
Authors 
Ashleigh M. Saenz, Stacie Stapleton, Raquel G. Hernandez, Greg A. Hale, Neil A. Goldenberg, Skai W. 
Schwartz, and Ernest K. Amankwah 
This article is available at Scholar Commons: https://scholarcommons.usf.edu/epb_facpub/5 
Research Article
BodyMass Index at Pediatric LeukemiaDiagnosis and the Risks of
Relapse and Mortality: Findings from a Single Institution
and Meta-analysis
Ashleigh M. Saenz,1 Stacie Stapleton,2,3 Raquel G. Hernandez,2,4 Greg A. Hale,2,3,5
Neil A. Goldenberg,2,3,6 Skai Schwartz,1 and Ernest K. Amankwah 3,5
1Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, USA
2Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3Cancer and Blood Disorders Institute, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, USA
4Office of Medical Education, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, USA
5Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
6Clinical and Translational Research Organization, All Children’s Research Institute, Johns Hopkins All Children’s Hospital,
St. Petersburg, FL, USA
Correspondence should be addressed to Ernest K. Amankwah; ernie.amank@gmail.com
Received 2 November 2017; Accepted 4 October 2018; Published 1 November 2018
Guest Editor: Nasrin Shoar
Copyright © 2018 Ashleigh M. Saenz et al. ,is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
High body mass index (BMI) is associated with relapse of certain adult cancers, but limited knowledge exists on its association
with pediatric leukemia relapse. We evaluated the association between overweight/obesity (BMI ≥ 85th percentile) at pediatric
leukemia diagnosis and relapse or mortality. A meta-analysis combining our findings with those of previous studies was also
performed. ,e study included 181 pediatric leukemia patients. Sporadic missing data were multiply imputed, and hazard ratios
(HR) and 95% confidence intervals (95% CI) were calculated using Cox proportional hazard. Age- and sex-adjusted analysis for
patients ≥10 years showed a trend towards increased risk of relapse for overweight/obese patients (HR � 2.89, 95% CI � 0.89–9.36,
p � 0.08) that was not evident among children<10 years (HR � 0.52, 95% CI � 0.08–3.54, p � 0.49). We observed a statistically
significant association between mortality and obesity status in unadjusted models (imputed: HR � 2.54, 95% CI � 1.15–5.60,
p � 0.021; complete set: HR � 2.72, 95% CI � 1.26–5.91, p � 0.011) that was not statistically significant in both age- and sex-
adjusted and multivariable adjusted analyses. ,e pooled estimate of our finding and previous studies showed an association
between overweight/obese and increased risk of mortality for ALL (HR � 1.39, 95% CI � 1.16–1.46) and AML (HR � 1.64, 95% CI
� 1.32–2.04). Although our study did not observe statistically significant associations due to a small sample size, the meta-analyses
revealed an increased risk of mortality for overweight/obese patients. ,e findings of our study suggest an association of obesity
status with relapse in children ≥10 years. However, our study was based on a small sample size from a single institution, and this
association needs to be investigated in larger, multicenter studies.
1. Introduction
Leukemia is themost prevalent pediatric malignancy and the
leading cause of cancer-related death among youth [1].
Acute lymphocytic leukemia (ALL), the most common form
of leukemia, independently represents more than a quarter
of all cancer diagnoses among children aged 0–14 years
[2, 3]. Substantial improvement in therapy has resulted in
a dramatic increase in the survival rate for leukemia over the
past five decades, with 5-year overall survival now at about
80% for ALL [2, 3] and 60% for acute myeloid leukemia
(AML) [4, 5]. However, approximately 20–40% of pediatric
leukemia patients develop relapse and become refractory to
treatment [6–9].
Obesity has been associated with relapse of certain adult
cancers [10–12], but limited knowledge exists on its association
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with pediatric leukemia relapse. Furthermore, findings from
the few studies in pediatrics have been inconsistent with some
studies reporting an increased risk of relapse with obesity
[13–15] while others have reported no association [16–21].
,e purpose of this study was to evaluate the association
between body mass index (BMI) at diagnosis and pediatric
(<21 years) leukemia relapse by comparing the risk for non-
overweight to overweight/obese patients. We hypothesized
that pediatric leukemia patients with a higher BMI at di-
agnosis are more likely to relapse than pediatric leukemia
patients with a normal or lower BMI at diagnosis. We also
evaluated the association between BMI at diagnosis and
overall mortality.
2. Materials and Methods
2.1. Study Design and Study Population. We conducted
a retrospective analysis on children diagnosed with leukemia
at Johns Hopkins All Children’s Hospital (JHACH, St.
Petersburg, FL). JHACH is a tertiary children’s hospital with
an established Cancer and Blood Disorders Institute that
serves as the largest pediatric cancer center in West Florida.
,e study was approved by JHACH Institutional Review
Board, with waiver of informed consent granted.
All patients with leukemia treated at JHACH were
considered eligible for the study. However, the analysis was
limited to patients diagnosed between April 2005 and De-
cember 2014 and followed through June 2016, because BMI
was not consistently collected in our database before this
period. Participants were identified via an electronic health
record-derived data warehouse using the first recorded
International Classification of Diseases, Ninth Revision
(ICD-9) codes 204.00–205.92. Diagnoses included ALL,
AML, and chronic myeloid leukemia (CML). We reviewed
the records of 194 patients with leukemia treated with
AALL0932, AALL0434, AALL1131, and AALL0631 for ALL
and AAML0531 and AAML1031 for AML. We excluded
patients diagnosed at an age younger than 2 years (n � 7)
(because BMI percentile calculation is not recommended for
this age group [22], those who never achieved remission
(n � 3), patients with a secondary malignancy (n � 2) and
one patient with myelodysplastic syndrome. ,e final
analysis included 181 patients (Figure 1). De-identified
patient demographic and clinical information, including
age, sex, insurance type, white blood cell (WBC) count, BMI
at diagnosis, relapse, and mortality status as well as follow-
up time were obtained from the data warehouse or through
patient chart review.
BMI at diagnosis was calculated as weight (kilograms)
divided by the square of height (meters). BMI percentiles
were determined using the 2000 Centers for Disease
Control and Prevention (CDC) BMI for age growth charts
for children between 2 and 20 years of age [23]. Participants
were classified according to age-adjusted BMI percentiles
as overweight/obese (≥85th percentile) and non-overweight
(<85th percentile). ,e insurance type was categorized as
public (Medicaid, Medicaid HMO) versus private (all
others) class.
2.2. Statistical Methods. Demographic and clinical charac-
teristics were summarized by obesity status using median
and range for continuous variables and counts and per-
centages for categorical variables. Duration of relapse-free
survival (RFS) was defined as the time from diagnosis date to
the first documentation of any relapse. Duration of overall
survival (OS) was defined as the time from diagnosis date to
the date of death. Patients who were lost to follow-up or who
did not experience an event were censored at the date of last
contact.
A complete set analysis and an analysis after multiple
imputation of missing values for both response (relapse,
n � 28) and independent variables (BMI � 25, insurance type,
n � 5, and WBC, n � 29) were performed. Five multiply
imputed datasets were first generated. Each imputed dataset
was analyzed using standard procedures, and then the results
from the five datasets were combined for inference. Hazard
ratios (HRs) and 95% confidence intervals (95% CI) from
unadjusted and multivariable adjusted Cox proportional
hazard models were used further to evaluate the association
between RFS or OS and obesity on the imputed dataset.
Multivariable models were adjusted for age (continuous), sex,
andWBC (continuous) at diagnosis based on previous studies
[24, 25] as well as insurance type (private/public), which is
associated with disease outcome [26]. Log-transformed WBC
was used in all models due to non-normality. In addition to
analyses that combined all participants, subgroup analyses
were conducted to investigate putative associations in dif-
ferent age groups. Previous studies have suggested that the
associations might be different among children older than 10
years and those younger than 10 years [13, 17]. ,erefore,
subgroup analyses were conducted among children ≥10 years
and children <10 years.
,e number of eligible patients treated at our institution
during the study period (n � 181) determined the sample
size. Assuming that 30% of the study participants were
overweight/obese [27] and that relapse occurs in 20% of
Eligible patients
(n = 194)
Final analysis
(n = 181)
Obesity status
measured
(n = 156)
Overweight/obese
(n = 45)
Nonobese
(n = 111)
Obesity status
imputed
(n = 25)
Exclusions:
(i) Age < 2 (n = 7)
(ii) Secondary cancer (n = 2)
(iii) Myelodysplastic syndrome (n = 1)
(iv) Never in remission (n = 3)
Figure 1: Diagram of eligible and included leukemia patients.
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patients, the study had at least 80% power at the 5% sig-
nificance level to detect a HR ≥ 2.8. Due to the small sample
size of our study, we performed a meta-analysis using
random effect models to pool our HRs from multivariable
adjusted models with those of previous studies that were
recently summarized by our group [28]. Statistical hetero-
geneity between study specific effects was evaluated with
Cochran’s Q test and quantified with I-squared statistic.
Descriptive statistics were performed using SAS version
9.4 and multiple imputation, Cox analyses and meta-
analyses were performed using Stata v 15. All statistical
tests were two-sided with a p value <0.05 considered sta-
tistically significant.
3. Results
Characteristics of patients with unimputed information on
obesity status are shown in Table 1. Approximately 29%
(45/156) of the patients were classified as overweight/obese.
Compared to non-overweight patients, overweight/obese
patients were older (median age: 13 vs 6 years), were
likely to have public insurance (53.3% vs 44.1%), to be di-
agnosed with AML (24.4% vs 12.6%), had a higher median
WBC count at diagnosis (11.9 × 103 vs 7.5 × 103/L) and
a longer median follow-up time (61.7 months vs 45.4
months). Twenty-seven percent of overweight/obese de-
veloped relapse (compared to 19% non-overweight), and
29% of overweight/obese died (compared to 12% non-
overweight). Death was mostly due to relapse (n � 15),
disease/treatment-related (n � 7), or other (n � 5). Results of
unadjusted and multivariable-adjusted analyses were similar
for imputed and complete set analyses (Tables 2 and 3). Age-
and sex-adjusted Cox proportional hazard regression ana-
lyses (Table 2) did not show a statistically significant asso-
ciation between relapse and obesity status, although the
association for children ≥10 years showed a trend towards
increased risk of relapse for overweight/obese patients
(imputed: HR � 2.89, 95% CI � 0.89–9.36, p � 0.08; com-
plete set: HR � 2.46, 95% CI � 0.96–7.27, p � 0.06) that was
not evident among children <10 years. However, the risks
attenuated slightly and were not statistically significant after
additional adjustment for insurance type and WBC at di-
agnosis (Supplementary Table 1). We observed a statistically
significant association between mortality and obesity status
in unadjusted models (imputed: HR � 2.54, 95% CI �
1.15–5.60, p � 0.021; complete set: HR � 2.72, 95% CI �
1.26–5.91, p � 0.011) that disappeared in both age- and sex-
adjusted and multivariable-adjusted analyses (Table 3,
Supplementary Table 1). Analyses limited to ALL, the most
common type of leukemia, did not show an association
between relapse or mortality (Table 4) and obesity status. As
expected, analysis based on the small number of AML cases
only did not show a statistically significant association for
relapse (HR � 3.93, 95% CI � 0.71–21.82, p � 0.12) or
mortality (HR � 1.39, 95% CI � 0.31–6.27, p � 0.67).
A meta-analysis combining our HRs from the multi-
variable models with those of previous studies showed as-
sociations between obesity and increased risk for mortality
(HR � 1.79, 95% CI � 1.03–3.10) and relapse (HR � 1.28,
95% CI � 1.04–1.57) for ALL, albeit the analysis for relapse
included only two studies (Figure 2). Similarly, we observed
an association between obesity and increased risk of mor-
tality for AML (HR � 1.64, 95% CI � 1.32–2.04) (Figure 3).
None of the studies that met inclusion for the meta-analysis
reported an estimate for AML relapse.
4. Discussion
In the present study, we evaluated the association between
obesity status and pediatric leukemia relapse and mortality.
We observed a trend towards an increased risk of relapse
associated with overweight/obesity in age- and sex-adjusted
model among children ≥10 years, but the trend disappeared
after additional adjustment for insurance type and WBC
at diagnosis. We observed an association between
overweight/obesity and mortality in unadjusted models, but
the association disappeared in multivariable models that
adjusted for factors including insurance type. However, the
results of a meta-analysis that combined our findings with
previous studies revealed an increased risk of mortality for
overweight/obesity.
,e relationship between obesity and cancer relapse is
biologically plausible as obesity may affect molecular path-
ways that are relevant to cancer progression [29, 30]. ,ough
this association has been observed in various adult cancers
[10–12], findings on the association between obesity and
pediatric leukemia relapse have been inconsistent. Weir et al.
[20] examined the effects of standardized deviation score for
BMI at diagnosis on leukemia relapse in children in the UK
(n � 1, 025) and did not observe a statistically significant
association between obesity and relapse. Another study in the
UK on a cohort of 1,033 patients found no evidence to
support the association between overweight/obesity at di-
agnosis and childhood leukemia relapse [16]. Findings from
two similar studies in the US by Hijiya et al. [18] and Bail-
largeon et al. [17] also failed to detect an association between
obesity at diagnosis and risk of relapse in children with ALL.
Another study in Turkey did not show a difference between
mean BMI at diagnosis between relapsed and nonrelapsed
patients [19]. Our finding is consistent with these studies.
However, other studies have reported an increased risk
of pediatric leukemia relapse with obesity. A large retro-
spective cohort study of 4,260 US patients with ALL found
obesity at time of diagnosis to be an independent predictor
of relapse in patients ≥10 years of age [13]. We observed
a similar trend in our study, but the association disappeared
after additional adjustment for insurance type and WBC at
diagnosis. ,e lack of association in our multivariable
analysis could potentially be due to the small sample size of
our study. A smaller historical cohort study of 181 youths
with ALL found an increased risk of relapse with obesity at
diagnosis in patients <10 years of age [15]. Similarly in
a previous smaller study (n � 78), Reilly and colleagues
observed an association between weight for height standard
deviation score and risk for relapse, with the highest risk
observed in children with a lower weight-for-height [14].
Among AML patients, Lohmann and colleagues did not find
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an association between BMI at diagnosis and prognosis for
children aged 2–9 years, but observed a trend for improved
outcome in overweight patients aged 10–17 years [31]. Inabi
and colleagues observed a higher risk of mortality for
overweight/obese AML patients [21]. Although our findings
for AML were not statistically significant (due to small
Table 2: Hazard ratios for the association between obesity status and relapse-free survival.
Imputed Complete set
Variables HR∗ Lower 95% CI Upper 95% CI p-value HR∗ Lower 95% CI Upper 95% CI p-value
Unadjusted
All
Overweight/obese vs non-overweight 1.77 0.91 3.46 0.09 1.75 0.85 3.40 0.13<10 years
Overweight/obese vs non-overweight 0.52 0.08 3.39 0.48 0.33 0.04 2.56 0.29≥10 years
Overweight/obese vs non-overweight 2.39 0.79 7.26 0.12 2.17 0.78 6.01 0.14
Sex and/or age adjusted
All
Overweight/obese vs non-overweight 1.57 0.71 3.45 0.26 1.45 0.67 3.14 0.34
Female vs male 0.56 0.29 1.08 0.08 0.46 0.22 0.99 0.046
Age at diagnosis 1.07 1.02 1.13 0.012 1.11 1.04 1.18 0.002<10 years
Overweight/obese vs non-overweight 0.52 0.08 3.54 0.49 0.31 0.04 2.46 0.27
Female vs male 1.01 0.42 2.43 0.99 1.23 0.44 3.46 0.70≥10 years
Overweight/obese vs non-.
overweight 2.89 0.89 9.36 0.08 2.46 0.96 7.27 0.06
Female vs male 0.31 0.11 0.90 0.031 0.19 0.05 0.67 0.009∗Hazard ratio.
Table 1: Characteristics at diagnosis for pediatric leukemia patients by obesity status.
All
Obesity
Non-overweight
(n � 111)
Overweight/obese
(n � 45)
N % N % N %
Gender
Female 73 46.79 51 45.95 22 48.89
Male 83 53.21 60 54.05 23 51.11
Age at diagnosis (yrs), median (range) 156 7 (2–20) 111 6 (2–19) 45 13 (2–20)<10 102 65.38 84 75.68 18 40≥10 54 34.62 27 24.32 27 60
Race/ethnicity
Asian 6 3.85 4 3.6 2 4.44
Black 11 7.05 7 6.31 4 8.89
Caucasian 98 62.82 76 68.47 22 48.89
White Hispanic 34 21.79 19 17.12 15 33.33
Other 7 4.49 5 4.5 2 4.44
Insurance type
Private 80 51.28 62 55.86 18 40
Public 73 46.79 49 44.14 24 53.33
Missing 3 1.92 0 0 3 6.67
Type of leukemia
ALL 123 78.85 93 83.78 30 66.67
AML 25 16.03 14 12.61 11 24.44∗Other 8 5.13 4 3.6 4 8.89
WBC, median (range) 9.46 (0.21–744.0) 7.45 (0.72–402.6) 11.86 (0.21–744.0)<50 × 103/L 118 75.64 87 78.38 31 68.89≥50 × 103/L 25 16.03 13 11.71 12 26.67
Missing 13 8.33 11 9.91 2 4.44
Follow-up time (months), median (range) 57.04 (0.42–260.75) 45.42 (0.92–250.5) 61.67 (0.42–260.75)∗Other includes Burkitt cell leukemia, chronic myelogenous leukemia, BCR/ABL positive, chronic myeloid leukemia, NOS, anaplastic large cell lymphoma,
T-cell and Null-cell type, and juvenile myelomonocytic leukemia.
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Table 4: Association between obesity and relapse or mortality among pediatric ALL patients.
Imputed Complete set
Variables HR∗ Lower 95% CI Upper 95% CI p-value HR∗ Lower 95% CI Upper 95% CI p-value
Relapse
Unadjusted
Overweight/obese vs non-
overweight 1.09 0.43 2.76 0.86 0.99 0.36 2.67 0.98
Sex and age adjusted
Overweight/obese vs non-
overweight 1.00 0.35 2.84 0.99 0.88 0.31 2.48 0.81
Female vs male 0.79 0.37 1.69 0.55 0.65 0.27 1.55 0.33
Age at diagnosis 1.05 0.98 1.12 0.17 1.09 1.00 1.17 0.04
Multivariable adjusted
Overweight/obese vs non-
overweight 0.95 0.32 2.84 0.93 0.74 0.22 2.46 0.62
Female vs male 0.71 0.33 1.53 0.38 0.65 0.25 1.68 0.37
Age at diagnosis 1.07 0.99 1.16 0.08 1.13 1.03 1.25 0.011
Public vs private 1.87 0.80 4.38 0.15 2.20 0.79 6.15 0.13
WBC at diagnosis 0.97 0.73 1.28 0.81 0.92 0.68 1.26 0.61
Mortality
Unadjusted
Overweight/obese vs non-
overweight 2.58 0.84 7.92 0.10 2.83 0.95 8.46 0.06
Sex and age adjusted
Overweight/obese vs non-
overweight 1.61 0.43 6.33 0.47 1.89 0.60 6.00 0.28
Female vs male 0.77 0.27 2.20 0.63 0.52 0.16 1.74 0.29
Age at diagnosis 1.20 1.09 1.33 <0.001 1.25 1.10 1.42 <0.001
Table 3: Hazard ratios for the association between obesity status and overall survival.
Imputed Complete set
Variables HR∗ Lower 95% CI Upper 95% CI p-value HR∗ Lower 95% CI Upper 95% CI p-value
Unadjusted
All
Overweight/obese vs non-
overweight 2.54 1.15 5.60 0.021 2.72 1.26 5.91 0.011<10 years
Overweight/obese vs non-
overweight 0.93 0.10 8.57 0.94 1.07 0.12 9.59 0.95≥10 years
Overweight/obese vs non-
overweight 1.74 0.67 4.56 0.25 1.75 0.70 4.36 0.23
Sex and/or age adjusted
All
Overweight/obese vs non-
overweight 1.60 0.62 4.12 0.32 1.72 0.75 3.93 0.20
Female vs male 0.48 0.22 1.08 0.08 0.40 0.16 0.95 0.039
Age at diagnosis 1.18 1.09 1.27 <0.001 1.20 1.10 1.30 <0.001<10 years
Overweight/obese vs non-
overweight 0.89 0.09 8.62 0.92 1.05 0.17 9.39 0.97
Female vs male 1.63 0.36 7.32 0.53 1.61 0.27 9.65 0.60≥10 years
Overweight/obese vs non-
overweight 2.13 0.77 5.88 0.14 2.22 0.89 5.51 0.09
Female vs male 0.29 0.10 0.80 0.017 0.22 0.07 0.66 0.007∗Hazard ratio.
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numbers), the observed HRs were in the direction of an
increased risk. Future studies should investigate the asso-
ciation between obesity and AML outcomes.
Evidence from these previous studies suggest that the
inconsistency in study findings may not be attributed to
sample size, since an association or lack of an association is
observed in both large and small studies. Our findings
suggested a trend towards an increased risk of relapse for
overweight/obese patients among children ≥10 years old.
,e association may be limited to a certain pediatric age
group and thus not evident in studies that do not stratify on
age. ,erefore, future larger multicenter studies that will
stratify analyses on age are warranted to provide further
insights into the relationship between obesity at diagnosis
and pediatric leukemia relapse. Existing evidence suggests
that White Hispanics have a higher risk of relapse and
mortality compared to other racial/ethnic groups [32, 33].
Since the distribution of obesity also varies by ethnicity [34],
it is important to also evaluate the association between
obesity and outcomes by race/ethnicity.
Our meta-analyses findings suggested an increased risk
of mortality for overweight/obese patients that is consistent
with the result of a recent meta-analysis [28]. ,e meta-
analysis including a total of 916 cases from seven studies
[17, 24, 35–39] showed an increased risk of mortality for
overweight/obese patients and suggested that about 5% of
the pediatric leukemia deaths could potentially be attributed
to overweight/obesity. ,e management of obesity could
therefore be considered during treatment to improve sur-
vival outcomes for patients with a high BMI at diagnosis.
Potential strengths of this study include the restriction of
analyses to patients with leukemia (as some of the prior
studies included patients with various forms of hematologic
conditions [35, 36] and the adjustment for age, sex, WBC at
diagnosis, and insurance type in our multivariable analyses.
Information for BMI and WBC at diagnosis was missing for
some patients because they were not diagnosed at our in-
stitution. We therefore performed multiple imputations for
the missing information. ,e majority of previous studies
performed a complete set analysis or/and did not adjust for
insurance type (which is suggested to affect cancer outcome
[40–43]) in multivariable models.
,e main limitation of our study is the small sample size,
which limited the analysis for each leukemia subtype. Lumping
all forms of leukemias together could potentially distort
Table 4: Continued.
Imputed Complete set
Variables HR∗ Lower 95% CI Upper 95% CI p-value HR∗ Lower 95% CI Upper 95% CI p-value
Multivariable adjusted
Overweight/obese vs non-
overweight 1.52 0.38 6.10 0.54 2.00 0.50 8.12 0.33
Female vs male 0.63 0.21 1.88 0.41 0.35 0.08 1.46 0.15
Age at diagnosis 1.21 1.09 1.34 <0.001 1.30 1.12 1.52 0.001
Government vs commercial 2.24 0.70 7.13 0.17 1.98 0.51 7.62 0.32
WBC at diagnosis 1.24 0.93 1.64 0.14 1.21 0.87 1.68 0.26∗Hazard ratio.
Butturini
Our study
.5 1 2.5 5 10
Overall (I-squared = 0.0%, p = 0.590)
2007 1.29 (1.04, 1.60)
0.95 (0.32, 2.83)
1.28 (1.04, 1.57)
3917
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Hazard
ratio (95% CI)Study Year N
(a)
Baillargeon
Ethier
Our study
.5 1 2.5 5 10
Overall (I-squared = 0.0%, p = 0.371)
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Figure 2: Meta-analyses combining the results of relapse (a) and overall survival (b) for ALL from this study with previous studies.
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Hazard
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Figure 3: Meta-analyses combining the results of overall survival
for AML from this study with previous studies.
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associations with specific leukemias. We performed analyses
limited to ALL, the most common type of leukemia. ,ough
the effect estimates of these analyses did not vary appreciably
from that of all leukemias combined, none of the associations
were statistically significant possibly due to the small sample
size. Another limitation is the grouping of overweight and
obesity together. ,is grouping may represent a more het-
erogeneous adiposity profile, which could potentially mask an
association between obesity and relapse or mortality.We could
not also adjust for several important potential confounding
factors such as cytogenetic-defined risk groups, T phenotype,
B-precursor subgroup, immunophenotype, and minimal re-
sidual disease. In addition, the study was a secondary analysis
of administrative data that were not collected for research
purposes and more specifically, to investigate the relationship
between obesity and pediatric leukemia relapse. As a result, we
were limited in the scope of analysis that could be performed.
We also used BMI as a measure of obesity. It is important to
note that reliance on BMI as an anthropomorphic measure of
obesity does not elucidate fat and lean muscle mass content.
While BMI is a universally accepted method to approximate
body composition, future studies would benefit from coupling
it with other measures of body composition such as Dual
energy X-ray absorptiometry (DEXA) scans and bio-
impedance. Another limitation is the use of insurance type as
a proxy for socioeconomic status (SES). We did not have
information on parental educational level, occupation, and/or
income, which may be better measures of SES. However,
insurance status has been associated with income whereby
public insurance is associated with low SES [44, 45]. In ad-
dition, we did not exclude patients with concomitant condi-
tions that have been associated with obesity and leukemia
outcomes such as Down syndrome. Despite these limitations,
some of the trends observed in our study are interesting and
could be evaluated further in larger studies.
Obesity represents a rare opportunity for preventive in-
tervention that could improve outcomes; therefore, un-
derstanding the prognostic impact of obesity on pediatric cancer
outcomes has both clinical and public health implications.
Although our study did not find statistically significant asso-
ciations between overweight/obesity and relapse or mortality
due to the small sample size, the findings from meta-analyses
revealed an increased risk of mortality for overweight/obese
patients. In addition, our findings may suggest a potential as-
sociation between obesity and relapse that may be limited to
children ≥10 years. However, our study was based on a small
sample size from a single institution, and this association needs
to be further investigated in larger, multicenter studies.
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